Skyclarys belongs to a group of medicines classed as “orphan drugs”, which are designed to treat rare diseases. Orphan drugs often come with a pretty hefty price tag. Without these orphan drugs, there is a significant unmet need. Rare disease patients in Ireland are suffering. This is why it is so essential that Ireland develops a robust approach to approving and reimbursing orphan drugs.

Source: Irish Examiner January 26, 2026 10:00 UTC